Literature DB >> 20238478

Estrogens, regulation of p53 and breast cancer risk: a balancing act.

D Joseph Jerry1, Karen A Dunphy, Mary J Hagen.   

Abstract

The paradoxical effects of ovarian hormones in both the promotion and prevention of breast cancer have been debated for over 30 years. Genetic studies have demonstrated that ovarian hormones act through NF-kappaB to stimulate proliferation and ductal elongation, whereas the p53 tumor suppressor protein plays a central role in rendering the mammary epithelium resistant to tumorigenesis. Transcriptional profiles now suggest that ovarian hormones stimulate a constellation of genes that interact with NF-kappaB and p53 to arbitrate the competing demands for proliferation and surveillance. Genes that participate in chromatin remodeling are among the acute transcriptional responses to estrogens and progestins. These genes are proposed to initiate epigenetic programs that influence the balance between proliferation and surveillance, and render the breast epithelium resistant to tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20238478     DOI: 10.1007/s00018-009-0244-7

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  73 in total

1.  Early growth response 1 protein, an upstream gatekeeper of the p53 tumor suppressor, controls replicative senescence.

Authors:  Anja Krones-Herzig; Eileen Adamson; Dan Mercola
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

2.  IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development.

Authors:  Y Cao; G Bonizzi; T N Seagroves; F R Greten; R Johnson; E V Schmidt; M Karin
Journal:  Cell       Date:  2001-12-14       Impact factor: 41.582

3.  Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland.

Authors:  Sonia Mallepell; Andrée Krust; Pierre Chambon; Cathrin Brisken
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-01       Impact factor: 11.205

4.  Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1.

Authors:  Wei Zheng; Jirong Long; Yu-Tang Gao; Chun Li; Ying Zheng; Yong-Bin Xiang; Wanqing Wen; Shawn Levy; Sandra L Deming; Jonathan L Haines; Kai Gu; Alecia Malin Fair; Qiuyin Cai; Wei Lu; Xiao-Ou Shu
Journal:  Nat Genet       Date:  2009-02-15       Impact factor: 38.330

5.  Chemoprevention of N-nitroso-N-methylurea-induced mammary cancers by pretreatment with 17 beta-estradiol and progesterone.

Authors:  C J Grubbs; D R Farnell; D L Hill; K C McDonough
Journal:  J Natl Cancer Inst       Date:  1985-04       Impact factor: 13.506

6.  Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells.

Authors:  Frank J Secreto; David G Monroe; Shamit Dutta; James N Ingle; Thomas C Spelsberg
Journal:  J Cell Biochem       Date:  2007-08-01       Impact factor: 4.429

7.  Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta.

Authors:  G G Kuiper; J G Lemmen; B Carlsson; J C Corton; S H Safe; P T van der Saag; B van der Burg; J A Gustafsson
Journal:  Endocrinology       Date:  1998-10       Impact factor: 4.736

8.  Transcriptional responses to estrogen and progesterone in mammary gland identify networks regulating p53 activity.

Authors:  Shaolei Lu; Klaus A Becker; Mary J Hagen; Haoheng Yan; Amy L Roberts; Lesley A Mathews; Sallie S Schneider; Hava T Siegelmann; Kyle J MacBeth; Stephen M Tirrell; Jeffrey L Blanchard; D Joseph Jerry
Journal:  Endocrinology       Date:  2008-06-12       Impact factor: 4.736

9.  A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women.

Authors:  Sandrine Tchatchou; Anke Jung; Kari Hemminki; Christian Sutter; Barbara Wappenschmidt; Peter Bugert; Bernhard H F Weber; Dieter Niederacher; Norbert Arnold; Raymonda Varon-Mateeva; Nina Ditsch; Alfons Meindl; Rita K Schmutzler; Claus R Bartram; Barbara Burwinkel
Journal:  Carcinogenesis       Date:  2008-11-20       Impact factor: 4.944

10.  Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer.

Authors:  Chin-Yo Lin; Anders Ström; Say Li Kong; Silke Kietz; Jane S Thomsen; Jason B S Tee; Vinsensius B Vega; Lance D Miller; Johanna Smeds; Jonas Bergh; Jan-Ake Gustafsson; Edison T Liu
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  10 in total

1.  RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor α.

Authors:  B Huang; Z Qu; C W Ong; Y-H N Tsang; G Xiao; D Shapiro; M Salto-Tellez; K Ito; Y Ito; L-F Chen
Journal:  Oncogene       Date:  2011-06-27       Impact factor: 9.867

2.  Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes.

Authors:  Madhura S Mehta; Alexei Vazquez; Diptee A Kulkarni; John E Kerrigan; Gurinder Atwal; Shoichi Metsugi; Deborah L Toppmeyer; Arnold J Levine; Kim M Hirshfield
Journal:  Breast Cancer Res Treat       Date:  2010-07-25       Impact factor: 4.872

Review 3.  Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.

Authors:  Priscilla A Furth; M Carla Cabrera; Edgar S Díaz-Cruz; Sarah Millman; Rebecca E Nakles
Journal:  Ann N Y Acad Sci       Date:  2011-07       Impact factor: 5.691

4.  Map making in the 21st century: charting breast cancer susceptibility pathways in rodent models.

Authors:  Anneke C Blackburn; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-03-08       Impact factor: 2.673

5.  Interferon regulatory factor 4 binding protein is a novel p53 target gene and suppresses cisplatin-induced apoptosis of breast cancer cells.

Authors:  Mingzhen Yang; Fang Yuan; Peng Li; Zhongjiao Chen; An Chen; Shuhui Li; Chuanmin Hu
Journal:  Mol Cancer       Date:  2012-08-13       Impact factor: 27.401

Review 6.  Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence.

Authors:  Eileen M McGowan; Yiguang Lin; Diana Hatoum
Journal:  Cancers (Basel)       Date:  2018-05-31       Impact factor: 6.639

7.  Long non-coding RNAs may serve as biomarkers in breast cancer combined with primary lung cancer.

Authors:  Xianfeng Ding; Yuhan Zhang; Hongjian Yang; Weimin Mao; Bo Chen; Shifeng Yang; Xiaowen Ding; Dehong Zou; Wenju Mo; Xiangming He; Xiping Zhang
Journal:  Oncotarget       Date:  2017-04-21

8.  Oxybenzone Alters Mammary Gland Morphology in Mice Exposed During Pregnancy and Lactation.

Authors:  Charlotte D LaPlante; Ruby Bansal; Karen A Dunphy; D Joseph Jerry; Laura N Vandenberg
Journal:  J Endocr Soc       Date:  2018-05-22

9.  Regulation of p53 level by UBE4B in breast cancer.

Authors:  Ying Zhang; Yanrong Lv; Yongyang Zhang; Haidong Gao
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

Review 10.  Adverse outcome pathways for ionizing radiation and breast cancer involve direct and indirect DNA damage, oxidative stress, inflammation, genomic instability, and interaction with hormonal regulation of the breast.

Authors:  Jessica S Helm; Ruthann A Rudel
Journal:  Arch Toxicol       Date:  2020-05-13       Impact factor: 5.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.